Science Fiction Becomes Fact: Neoantigen Therapy in Melanoma Science Fiction Becomes Fact: Neoantigen Therapy in Melanoma
Prof David Kerr discusses neoantigen therapy for patients with melanoma. (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 6, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
U.S. FDA Approves Expanded Use Of J & J's Cancer Cell Therapy U.S. FDA Approves Expanded Use Of J & J's Cancer Cell Therapy
The U.S. Food and Drug Administration on Friday allowed the expanded use of Johnson& Johnson and Legend Biotech ' s Carvykti cell therapy as an earlier treatment for...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 6, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Cancer 'Tidal Wave' Forecast; Not Decaf, Too! Cautionary Tales of Cancer, Cannabis
(MedPage Today) -- If projected changes in population growth and aging hold, a "tidal wave" of cancer cases could increase the worldwide prevalence by 77% over the next 25 years. (CA: A Cancer Journal for Clinicians)
A cancer "previvor" clinic... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 5, 2024 Category: Hematology Source Type: news
Medicare IHC Claims With Melanoma Dxs Increased, Study Finds Medicare IHC Claims With Melanoma Dxs Increased, Study Finds
With sparse guidance regarding best practices for IHC in melanoma diagnosis, more research is needed to optimize use of IHC in this setting, according to the authors.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 5, 2024 Category: Cancer & Oncology Tags: Dermatology Source Type: news
Oncology Practice and Lab to Pay $4 Million in Kickback Case Oncology Practice and Lab to Pay $4 Million in Kickback Case
San Antonio –based healthcare providers have agreed to pay over $4 million in civil settlements to resolve allegations of violating the False Claims Act through an unlawful kickback arrangement.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 5, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
AstraZeneca's Imfinzi Improves Survival in Late-stage Lung Cancer Trial AstraZeneca's Imfinzi Improves Survival in Late-stage Lung Cancer Trial
AstraZeneca said on Friday its blockbuster cancer drug Imfinzi helped improve survival in patients in the early stages of an aggressive type of lung cancer, making it the...Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 5, 2024 Category: Allergy & Immunology Tags: Hematology-Oncology Source Type: news
Prostate Cancer Tsunami Coming, Experts Caution Prostate Cancer Tsunami Coming, Experts Caution
A Lancet commission is predicting an 85% increase in deaths from the disease by 2040.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 5, 2024 Category: Cancer & Oncology Tags: Urology Source Type: news
Word Choice and Royals: The Need To Be Clear and Precise Word Choice and Royals: The Need To Be Clear and Precise
Dr Mark Lewis discusses the importance of word choice related to cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 4, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
' Nothing Rivaled This': Navigating the Cancer Drug Shortage'Nothing Rivaled This': Navigating the Cancer Drug Shortage
Because this platinum drug shortage crisis won ' t be the last, oncology practices need to be better prepared to tackle future problems.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 4, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Factor D Inhibitor Wins Approval for PNH With Extravascular Hemolysis
(MedPage Today) -- The FDA approved the oral factor D inhibitor danicopan (Voydeya) as an add-on therapy to treat extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH), AstraZeneca announced.
The approval specifies use... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 4, 2024 Category: Hematology Source Type: news
Less Neck Radiation Effective in Early Nasopharyngeal Cancer Less Neck Radiation Effective in Early Nasopharyngeal Cancer
Omitting radiation to the lower-neck region in patients with early-stage nasopharyngeal cancer provided similar survival outcomes and reduced long-term toxicity compared to whole-neck irradiation.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 4, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
New study paves the way for precision drugs to treat blood cancers
The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive activation and cytokine-independent signaling and underlie several hematological malignancies from myeloproliferative neoplasms (MPN) to acute leukemia and lymphomas. JAK2 contains an active kinase domain and an inactive pseudokinase domain. Interestingly, pathogenic mutations mainly occur in the regulatory pseudokinase domain. (Source: World Pharma News)
Source: World Pharma News - April 4, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Sanofi to Settle 4,000 Zantac Cancer Lawsuits in US State Courts Sanofi to Settle 4,000 Zantac Cancer Lawsuits in US State Courts
Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on...Reuters Health Information (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 3, 2024 Category: Internal Medicine Tags: Hematology-Oncology Source Type: news
Evidence Strengthens for De-Escalating Axillary Surgery in Breast Cancer
(MedPage Today) -- The concept of skipping axillary lymph node dissection (ALND) in some patients with breast cancer was supported by a European noninferiority trial.
Among patients with early-stage, node-negative breast cancer and one or two... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 3, 2024 Category: Hematology Source Type: news
Polygenic Risk Scores Improve Breast Cancer Screening Polygenic Risk Scores Improve Breast Cancer Screening
A Finnish study shows that adding polygenic risk scores to positive family histories and breast cancer-associated gene mutations improves risk stratification for breast cancer screening.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 3, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
